Biotech firm NeOnc Technologies has gained rapid attention after going public in March 2025 and joining the Russell Microcap Index just months later. The company focuses on intranasal drug delivery for brain cancer, allowing patients to administer treatment at home and bypass the blood-brain barrier.
NeOnc's lead treatment is in Phase 2A trials for glioblastoma patients and is already showing extended survival times with minimal side effects. Backed by a partnership with USC's Keck Medical School, the company is also expanding clinical trials to the Middle East and North Africa under US FDA standards.
A $50 million investment deal with a UAE-based firm is helping fund this expansion, including trials run by Cleveland Clinic through a regional partnership. The trials are expected to be fully enrolled by September, with positive preliminary data already being reported.
AI and quantum computing are central to NeOnc's strategy, particularly in reducing risk and cost in trial design and drug development. As a pre-revenue biotech, the company is betting that innovation and global collaboration will carry it to the next stage of growth.
